15 April 2024According to this retrospective study, melanoma patients receiving radiotherapy (RT) in combination with immune checkpoint inhibitors (ICI) had a superior antitumoral response in both irradiated and non-irradiated lesions as compared to patients receiving only RT. Additionally, a subgroup of patients receiving RT when progressing on ICI experienced tumor regression also in non-irradiated areas.
15 April 2024According to this recent study, adjuvant mRNA-4157 plus pembrolizumab prolonged recurrence-free survival versus pembrolizumab monotherapy in patients with resected high-risk melanoma, and showed a manageable safety profile. These results provide evidence that an mRNA-based individualised neoantigen therapy might be beneficial in the adjuvant setting.
15 April 2024This study aimed to determine lateral and deep margins in keratinocytic cancer excisions performed by GPs (in a private setting) and plastic surgeons (in a private or public setting) after a teledermatologist had confirmed that excision was necessary. The study concludes that GPs were less likely than specialist surgeons to respect surgical margin recommendations established in international guidelines for managing keratinocytic cancer.
15 April 2024The aim of this study was to evaluate an excision pathway for keratinocytic cancers (KC) diagnosed by teledermatology. The study reports prompt excision of KCs by general practitioners after an e-referral and a teledermatology response.
13 April 2024Adjuvant pembrolizumab significantly improved recurrence-free survival (RFS) and distant metastasis-free survival (DMFS) versus placebo in the phase 3 KEYNOTE-716 study of resected stage IIB or IIC melanoma. According to this recent post hoc analysis of efficacy by subtypes defined by histopathologic characteristics, the benefit of pembrolizumab was largely consistent with the overall study population regardless of histopathologic characteristics. These results support the use of adjuvant pembrolizumab in patients with resected stage IIB or IIC melanoma.
17 March 2024This recent paper aims to establish how New Zealand is doing in dealing with cancer. It compares New Zealand's performance with other countries, including Australia.
17 March 2024Researchers of this recent study identified various challenges when Artificial intelligence (AI) programs used for dermatologic purposes are applied to skin of color (SOC). They mainly stem from the underrepresentation of SOC in datasets and issues with image quality and standardization.
17 March 2024A national targeted melanoma screening program in Australia is a step closer following the recent release of the ‘Skin Checks for Melanoma in Australia Position Statement’, led by Melanoma Institute Australia in collaboration with expert colleagues from across the country.
16 March 2024Authors of this article summarise results from the ongoing phase 3 CheckMate 76K clinical study published online in Nature Medicine in October 2023. Results from CheckMate 76K support the benefit of using nivolumab as a treatment option for people with stage 2 melanoma post-surgery.
16 March 2024According to this recent study, there is benefit in the use of serious games in combination with Augmented Reality to educate and motivate users to perform skin self-examinations (SSE).
